Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Ensemble of Convolutional Neural Networks Improves Automated Segmentation of Acute Ischemic Lesions Using Multiparametric Diffusion-Weighted MRI.

Winzeck S, Mocking SJT, Bezerra R, Bouts MJRJ, McIntosh EC, Diwan I, Garg P, Chutinet A, Kimberly WT, Copen WA, Schaefer PW, Ay H, Singhal AB, Kamnitsas K, Glocker B, Sorensen AG, Wu O.

AJNR Am J Neuroradiol. 2019 Jun;40(6):938-945. doi: 10.3174/ajnr.A6077. Epub 2019 May 30.

PMID:
31147354
2.

Reduced Ischemic Lesion Growth with Heparin in Acute Ischemic Stroke.

Rocha EA, Ji R, Ay H, Li Z, Arsava EM, Silva GS, Sorensen AG, Wu O, Singhal AB.

J Stroke Cerebrovasc Dis. 2019 Jun;28(6):1500-1508. doi: 10.1016/j.jstrokecerebrovasdis.2019.03.016. Epub 2019 Mar 29.

PMID:
30935810
3.

Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.

Boxerman JL, Zhang Z, Safriel Y, Rogg JM, Wolf RL, Mohan S, Marques H, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2018 Sep 3;20(10):1400-1410. doi: 10.1093/neuonc/noy049.

4.

New biomarker for acute ischaemic stroke: plasma glycogen phosphorylase isoenzyme BB.

Park KY, Ay I, Avery R, Caceres JA, Siket MS, Pontes-Neto OM, Zheng H, Rost NS, Furie KL, Sorensen AG, Koroshetz WJ, Ay H.

J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):404-409. doi: 10.1136/jnnp-2017-316084. Epub 2017 Oct 13.

PMID:
29030420
5.

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.

Gilbert MR, Pugh SL, Aldape K, Sorensen AG, Mikkelsen T, Penas-Prado M, Bokstein F, Kwok Y, Lee RJ, Mehta M.

J Neurooncol. 2017 Jan;131(1):193-199. doi: 10.1007/s11060-016-2288-5. Epub 2016 Oct 21.

6.

ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA; ACRIN 6684 Trial Group.

Clin Cancer Res. 2016 Oct 15;22(20):5079-5086. Epub 2016 May 16.

7.

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.

Ellingson BM, Kim E, Woodworth DC, Marques H, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Int J Oncol. 2015 May;46(5):1883-92. doi: 10.3892/ijo.2015.2891. Epub 2015 Feb 11.

8.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL.

Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.

9.

Emerging techniques and technologies in brain tumor imaging.

Ellingson BM, Bendszus M, Sorensen AG, Pope WB.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii12-23. doi: 10.1093/neuonc/nou221.

10.

Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Emblem KE, Farrar CT, Gerstner ER, Batchelor TT, Borra RJ, Rosen BR, Sorensen AG, Jain RK.

Nat Rev Clin Oncol. 2014 Oct;11(10):566-84. doi: 10.1038/nrclinonc.2014.126. Epub 2014 Aug 12. Review.

11.

Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.

Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER.

Oncologist. 2014 Jan;19(1):75-81. doi: 10.1634/theoncologist.2013-0101. Epub 2013 Dec 5.

12.

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.

Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64. doi: 10.1073/pnas.1318022110. Epub 2013 Nov 4.

13.

The medical device excise tax--over before it begins?

Sorensen AG.

N Engl J Med. 2013 Sep 5;369(10):982-3. doi: 10.1056/NEJMc1307587. No abstract available.

PMID:
24004138
14.

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR.

J Clin Invest. 2013 Sep;123(9):3659-63. doi: 10.1172/JCI67229. Epub 2013 Sep 3. Review.

15.

Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy.

Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG.

Nat Med. 2013 Sep;19(9):1178-83. doi: 10.1038/nm.3289. Epub 2013 Aug 18.

16.

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M.

J Clin Oncol. 2013 Sep 10;31(26):3212-8. doi: 10.1200/JCO.2012.47.2464. Epub 2013 Aug 12.

17.

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Boxerman JL, Zhang Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):945-54. doi: 10.1093/neuonc/not049. Epub 2013 Jun 19.

18.

Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.

Breuer J, Gutierrez J, Latchaw R, Lehr R, Sorensen AG.

J Magn Reson Imaging. 2014 Feb;39(2):410-8. doi: 10.1002/jmri.24180. Epub 2013 May 16.

PMID:
23681501
19.

Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.

Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Gilbert MR, Sorensen AG, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):936-44. doi: 10.1093/neuonc/not044. Epub 2013 May 3.

20.

A new early and automated MRI-based predictor of motor improvement after stroke.

Granziera C, Daducci A, Meskaldji DE, Roche A, Maeder P, Michel P, Hadjikhani N, Sorensen AG, Frackowiak RS, Thiran JP, Meuli R, Krueger G.

Neurology. 2012 Jul 3;79(1):39-46. doi: 10.1212/WNL.0b013e31825f25e7. Epub 2012 Jun 20.

PMID:
22722626
21.

Case records of the Massachusetts General Hospital. Case 17-2012. A 54-year-old man with visual-field loss and a mass in the brain.

Batchelor TT, Sorensen AG, Louis DN.

N Engl J Med. 2012 May 31;366(22):2112-20. doi: 10.1056/NEJMcpc1111574. No abstract available.

PMID:
22646634
22.

Diffusion tensor imaging shows structural remodeling of stroke mirror region: results from a pilot study.

Granziera C, Ay H, Koniak SP, Krueger G, Sorensen AG.

Eur Neurol. 2012;67(6):370-6. doi: 10.1159/000336062. Epub 2012 May 17.

PMID:
22614706
23.

Effects of MRI scan acceleration on brain volume measurement consistency.

Krueger G, Granziera C, Jack CR Jr, Gunter JL, Littmann A, Mortamet B, Kannengiesser S, Sorensen AG, Ward CP, Reyes DA, Britson PJ, Fischer H, Bernstein MA.

J Magn Reson Imaging. 2012 Nov;36(5):1234-40. doi: 10.1002/jmri.23694. Epub 2012 May 8.

24.

Evaluating effects of normobaric oxygen therapy in acute stroke with MRI-based predictive models.

Wu O, Benner T, Roccatagliata L, Zhu M, Schaefer PW, Sorensen AG, Singhal AB.

Med Gas Res. 2012 Mar 9;2(1):5. doi: 10.1186/2045-9912-2-5.

25.

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.

Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG.

Sci Transl Med. 2012 Jan 11;4(116):116ra4. doi: 10.1126/scitranslmed.3002693.

26.

Neurologic 3D MR spectroscopic imaging with low-power adiabatic pulses and fast spiral acquisition.

Andronesi OC, Gagoski BA, Sorensen AG.

Radiology. 2012 Feb;262(2):647-61. doi: 10.1148/radiol.11110277. Epub 2011 Dec 20.

27.

Incidental findings in brain MRI research: what do we owe our subjects?

Borra RJ, Sorensen AG.

J Am Coll Radiol. 2011 Dec;8(12):848-52. doi: 10.1016/j.jacr.2011.08.009.

PMID:
22137002
28.

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK.

Cancer Res. 2012 Jan 15;72(2):402-7. doi: 10.1158/0008-5472.CAN-11-2464. Epub 2011 Nov 29. Erratum in: Cancer Res. 2012 Jan 15;72(2):doi:10.1158/0008-5472.CAN-12-0113. Cancer Res. 2012 Mar 1;72(5):1316.

29.

DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study.

Thomalla G, Cheng B, Ebinger M, Hao Q, Tourdias T, Wu O, Kim JS, Breuer L, Singer OC, Warach S, Christensen S, Treszl A, Forkert ND, Galinovic I, Rosenkranz M, Engelhorn T, Köhrmann M, Endres M, Kang DW, Dousset V, Sorensen AG, Liebeskind DS, Fiebach JB, Fiehler J, Gerloff C; STIR and VISTA Imaging Investigators.

Lancet Neurol. 2011 Nov;10(11):978-86. doi: 10.1016/S1474-4422(11)70192-2. Epub 2011 Oct 4.

PMID:
21978972
30.

[Ketamine is used again by both physicians and addicts].

Sørensen AG, Barnung S, Rasmussen LS.

Ugeskr Laeger. 2011 Aug 29;173(35):2123-6. Danish.

PMID:
21884663
31.

Real-time motion and B0 correction for localized adiabatic selective refocusing (LASER) MRSI using echo planar imaging volumetric navigators.

Hess AT, Andronesi OC, Tisdall MD, Sorensen AG, van der Kouwe AJ, Meintjes EM.

NMR Biomed. 2012 Feb;25(2):347-58. doi: 10.1002/nbm.1756. Epub 2011 Jul 28.

32.

Correlation chemical shift imaging with low-power adiabatic pulses and constant-density spiral trajectories.

Andronesi OC, Gagoski BA, Adalsteinsson E, Sorensen AG.

NMR Biomed. 2012 Feb;25(2):195-209. doi: 10.1002/nbm.1730. Epub 2011 Jul 20.

33.

Fast radio-frequency enforced steady state (FRESS) spin echo MRI for quantitative T2 mapping: minimizing the apparent repetition time (TR) dependence for fast T2 measurement.

Cheung JS, Wang E, Zhang X, Mandeville E, Lo EH, Sorensen AG, Sun PZ.

NMR Biomed. 2012 Feb;25(2):189-94. doi: 10.1002/nbm.1729. Epub 2011 Jul 14.

34.

Severity of leukoaraiosis determines clinical phenotype after brain infarction.

Arsava EM, Bayrlee A, Vangel M, Rost NS, Rosand J, Furie KL, Sorensen AG, Ay H.

Neurology. 2011 Jul 5;77(1):55-61. doi: 10.1212/WNL.0b013e318221ad02. Epub 2011 Jun 22.

35.

Diffusion imaging with prospective motion correction and reacquisition.

Benner T, van der Kouwe AJ, Sorensen AG.

Magn Reson Med. 2011 Jul;66(1):154-67. doi: 10.1002/mrm.22837. Epub 2011 Feb 24.

36.

Prediction of early stroke risk in transient symptoms with infarction: relevance to the new tissue-based definition.

Arsava EM, Furie KL, Schwamm LH, Sorensen AG, Ay H.

Stroke. 2011 Aug;42(8):2186-90. doi: 10.1161/STROKEAHA.110.604280. Epub 2011 Jun 16.

37.

QUantitative Imaging of eXtraction of oxygen and TIssue consumption (QUIXOTIC) using venular-targeted velocity-selective spin labeling.

Bolar DS, Rosen BR, Sorensen AG, Adalsteinsson E.

Magn Reson Med. 2011 Dec;66(6):1550-62. doi: 10.1002/mrm.22946. Epub 2011 Jun 14.

38.

Imaging stroke patients with unclear onset times.

Wu O, Schwamm LH, Sorensen AG.

Neuroimaging Clin N Am. 2011 May;21(2):327-44, xi. doi: 10.1016/j.nic.2011.02.008. Review.

39.

Transient ischemic attack: definition, diagnosis, and risk stratification.

Sorensen AG, Ay H.

Neuroimaging Clin N Am. 2011 May;21(2):303-13, x. doi: 10.1016/j.nic.2011.01.013. Review.

40.

Multiparametric magnetic resonance imaging of brain disorders.

Wu O, Dijkhuizen RM, Sorensen AG.

Top Magn Reson Imaging. 2010 Apr;21(2):129-38. doi: 10.1097/RMR.0b013e31821e56c2.

41.

Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.

Kim H, Catana C, Ratai EM, Andronesi OC, Jennings DL, Batchelor TT, Jain RK, Sorensen AG.

Cancer Res. 2011 Jun 1;71(11):3745-52. doi: 10.1158/0008-5472.CAN-10-2991. Epub 2011 Apr 20.

42.

T1- and T2*-dominant extravasation correction in DSC-MRI: part I--theoretical considerations and implications for assessment of tumor hemodynamic properties.

Bjornerud A, Sorensen AG, Mouridsen K, Emblem KE.

J Cereb Blood Flow Metab. 2011 Oct;31(10):2041-53. doi: 10.1038/jcbfm.2011.52. Epub 2011 Apr 20.

43.

T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.

Emblem KE, Bjornerud A, Mouridsen K, Borra RJ, Batchelor TT, Jain RK, Sorensen AG.

J Cereb Blood Flow Metab. 2011 Oct;31(10):2054-64. doi: 10.1038/jcbfm.2011.39. Epub 2011 Apr 20.

44.

Vagus nerve stimulation reduces infarct size in rat focal cerebral ischemia: an unlikely role for cerebral blood flow.

Ay I, Sorensen AG, Ay H.

Brain Res. 2011 May 25;1392:110-5. doi: 10.1016/j.brainres.2011.03.060. Epub 2011 Mar 31.

45.

In vivo 31P spectroscopy by fully adiabatic extended image selected in vivo spectroscopy: a comparison between 3 T and 7 T.

Bogner W, Chmelik M, Andronesi OC, Sorensen AG, Trattnig S, Gruber S.

Magn Reson Med. 2011 Oct;66(4):923-30. doi: 10.1002/mrm.22897. Epub 2011 Mar 28.

46.
47.

Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG.

AJNR Am J Neuroradiol. 2011 Dec;32(11):1978-85. doi: 10.3174/ajnr.A2397. Epub 2011 Mar 10. Review.

48.

Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.

Farrar CT, Kamoun WS, Ley CD, Kim YR, Catana C, Kwon SJ, Rosen BR, Jain RK, Sorensen AG.

PLoS One. 2011 Mar 3;6(3):e17228. doi: 10.1371/journal.pone.0017228.

49.

Use of in vivo two-dimensional MR spectroscopy to compare the biochemistry of the human brain to that of glioblastoma.

Ramadan S, Andronesi OC, Stanwell P, Lin AP, Sorensen AG, Mountford CE.

Radiology. 2011 May;259(2):540-9. doi: 10.1148/radiol.11101123. Epub 2011 Feb 25.

50.

Diffusion and diffusion tensor imaging in brain cancer.

Gerstner ER, Sorensen AG.

Semin Radiat Oncol. 2011 Apr;21(2):141-6. doi: 10.1016/j.semradonc.2010.10.005. Review.

PMID:
21356481

Supplemental Content

Loading ...
Support Center